| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $249,985 | 1 | 5 |
Sells | $8,986,130 | 18 | 95 |
| ENRIGHT PATRICK G | director | 1 | $249,985 | 0 | $0 | $249,985 |
| Skelton Laurence Matthew | Chief Commercial Officer | 0 | $0 | 1 | $66,419 | $-66,419 |
| Brenner Robert | Chief Medical Officer | 0 | $0 | 1 | $90,307 | $-90,307 |
| Carter Jason S | Chief Legal Officer | 0 | $0 | 1 | $107,498 | $-107,498 |
| JOHNSON DAVID LEE | Chief Operating Officer | 0 | $0 | 1 | $108,276 | $-108,276 |
| Grant Sean | CHIEF FINANCIAL OFFICER | 0 | $0 | 1 | $207,778 | $-207,778 |
| Young Joseph R | SVP, FINANCE, CHIEF ACCT OFFCR | 0 | $0 | 2 | $566,738 | $-566,738 |
| Turner William D. | Chief Regulatory Officer | 0 | $0 | 4 | $1.45M | $-1.45M |
| Fordyce Marshall | PRESIDENT AND CEO | 0 | $0 | 7 | $6.39M | $-6.39M |
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK …
Over the last 12 months, insiders at Vera Therapeutics, Inc. have bought $249,985 and sold $8.99M worth of Vera Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Vera Therapeutics, Inc. have bought $15.23M and sold $16.97M worth of stock each year.
Highest buying activity among insiders over the last 12 months: ENRIGHT PATRICK G (director) — $249,985.
The last purchase of 5,882 shares for transaction amount of $249,985 was made by ENRIGHT PATRICK G (director) on 2025‑12‑11.
| 2026-09-15 | Sale | Fordyce Marshall | PRESIDENT AND CEO | 18,500 0.0283% | $37.00 | $684,500 | -9.65% | |
| 2026-09-02 | Sale | Fordyce Marshall | PRESIDENT AND CEO | 18,500 0.0254% | $35.12 | $649,642 | -13.12% | |
| 2026-07-07 | Sale | Fordyce Marshall | PRESIDENT AND CEO | 46,250 0.0634% | $42.30 | $1.96M | -24.49% | |
| 2026-06-23 | Sale | Fordyce Marshall | PRESIDENT AND CEO | 18,500 0.0256% | $37.93 | $701,769 | -13.48% | |
| 2026-05-12 | Sale | Fordyce Marshall | PRESIDENT AND CEO | 18,500 0.0258% | $36.74 | $679,747 | -8.26% | |
| 2026-04-14 | Sale | Fordyce Marshall | PRESIDENT AND CEO | 22,951 0.0346% | $44.05 | $1.01M | -22.84% | |
| 2026-02-23 | Sale | Fordyce Marshall | PRESIDENT AND CEO | 16,925 0.0241% | $41.98 | $710,578 | -16.21% | |
| 2026-02-23 | Sale | Grant Sean | CHIEF FINANCIAL OFFICER | 4,949 0.0071% | $41.98 | $207,778 | -16.21% | |
| 2026-02-23 | Sale | Young Joseph R | SVP, FINANCE, CHIEF ACCT OFFCR | 3,117 0.0044% | $41.98 | $130,864 | -16.21% | |
| 2026-02-23 | Sale | Skelton Laurence Matthew | Chief Commercial Officer | 1,582 0.0023% | $41.98 | $66,419 | -16.21% | |
| 2026-02-23 | Sale | Brenner Robert | Chief Medical Officer | 2,151 0.0031% | $41.98 | $90,307 | -16.21% | |
| 2026-02-23 | Sale | JOHNSON DAVID LEE | Chief Operating Officer | 2,579 0.0037% | $41.98 | $108,276 | -16.21% | |
| 2026-02-23 | Sale | Turner William D. | Chief Regulatory Officer | 2,187 0.0031% | $41.98 | $91,819 | -16.21% | |
| 2025-12-15 | Sale | Turner William D. | Chief Regulatory Officer | 10,000 0.0159% | $50.08 | $500,767 | -24.20% | |
| 2025-12-11 | ENRIGHT PATRICK G | director | 5,882 0.0085% | $42.50 | $249,985 | -18.50% | ||
| 2025-12-08 | Sale | Turner William D. | Chief Regulatory Officer | 10,000 0.0157% | $45.31 | $453,053 | -15.39% | |
| 2025-12-03 | Sale | Turner William D. | Chief Regulatory Officer | 10,000 0.0152% | $40.00 | $400,000 | -7.27% | |
| 2025-11-21 | Sale | Carter Jason S | Chief Legal Officer | 3,864 0.0059% | $27.82 | $107,498 | +32.43% | |
| 2025-11-11 | Sale | Young Joseph R | SVP, FINANCE, CHIEF ACCT OFFCR | 15,000 0.0282% | $29.06 | $435,875 | +25.11% | |
| 2025-06-24 | ENRIGHT PATRICK G | director | 40,607 0.063% | $22.35 | $907,635 | +51.77% |
| Grant Sean | CHIEF FINANCIAL OFFICER | 114181 0.1584% | $3.51M | 4 | 2 | +48.2% |
| Young Joseph R | SVP, FINANCE, CHIEF ACCT OFFCR | 64722 0.0898% | $1.99M | 2 | 5 | +91.54% |
| ENRIGHT PATRICK G | director | 5882 0.0082% | $180,636.22 | 6 | 0 | +64.74% |
| COMMODORE CAPITAL LP | 10 percent owner | 4400000 6.1057% | $135.12M | 1 | 1 | +19.9% |
| Sofinnova Venture Partners X, L.P. | 10 percent owner | 3467156 4.8113% | $106.48M | 3 | 0 | +74.47% |
| EMSTER KURT VON | director | 2960231 4.1078% | $90.91M | 2 | 0 | +58.05% |
| Abingworth LLP | 10 percent owner | 2960231 4.1078% | $90.91M | 1 | 0 | +57.41% |
| Katabi Maha | director | 2793987 3.8771% | $85.8M | 2 | 3 | +37.14% |
| Longitude Capital Partners IV, LLC | 10 percent owner | 1714285 2.3789% | $52.65M | 3 | 0 | +74.47% |
| SEIDENBERG BETH C | director | 131553 0.1826% | $4.04M | 19 | 3 | +96.79% |
$21,345,882 | 83 | 94.45% | $2.19B | |
$52,263,649 | 70 | 1.18% | $2.49B | |
$1,376,668 | 53 | 18.46% | $2.1B | |
$108,353,116 | 49 | 15.41% | $2.17B | |
$586,486,795 | 47 | 4.28% | $2.38B |
| Increased Positions | 149 | +87.65% | 18M | +28.31% |
| Decreased Positions | 79 | -46.47% | 9M | -14.21% |
| New Positions | 69 | New | 9M | New |
| Sold Out Positions | 21 | Sold Out | 4M | Sold Out |
| Total Postitions | 240 | +41.18% | 74M | +14.1% |
| Avoro Capital Advisors Llc | $301,930.00 | 8.87% | 6.21M | -90,000 | -1.43% | 2025-09-30 |
| Blackrock, Inc. | $206,498.00 | 6.07% | 4.25M | +81,650 | +1.96% | 2025-09-30 |
| Kynam Capital Management, Lp | $195,832.00 | 5.75% | 4.03M | +600,913 | +17.54% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $178,262.00 | 5.24% | 3.67M | -813,278 | -18.16% | 2025-09-30 |
| Deerfield Management Company, L.P. | $177,033.00 | 5.2% | 3.64M | +293,040 | +8.75% | 2025-09-30 |
| Vanguard Group Inc | $155,130.00 | 4.56% | 3.19M | +189,545 | +6.32% | 2025-09-30 |
| Fmr Llc | $138,233.00 | 4.06% | 2.84M | -66,833 | -2.3% | 2025-09-30 |
| Eversept Partners, Lp | $136,517.00 | 4.01% | 2.81M | +424,781 | +17.82% | 2025-09-30 |
| Sofinnova Investments, Inc. | $135,844.00 | 3.99% | 2.79M | 0 | 0% | 2025-09-30 |
| State Street Corp | $113,459.00 | 3.33% | 2.33M | +315,900 | +15.66% | 2025-09-30 |